ERBB2 and breast carcinoma: These data are consistent with observations that growth of tumors composed of ErbB2-positive breast cancer cells injected in immunodeficient mice is suppressed by trastuzumab much more efficiently if the drug is administered immediately after cell injection (before the tumor mass is formed) compared to the scenario when the drug is administered after a tumor mass is established [47].